S
Sibel Tekin
Researcher at Novartis
Publications - 22
Citations - 3221
Sibel Tekin is an academic researcher from Novartis. The author has contributed to research in topics: Rivastigmine & Dementia. The author has an hindex of 16, co-authored 22 publications receiving 3044 citations.
Papers
More filters
Journal ArticleDOI
Rivastigmine for Dementia Associated with Parkinson's Disease
Murat Emre,Dag Aarsland,Alberto Albanese,E. J. Byrne,Günther Deuschl,P.P. De Deyn,Franck Durif,Jaime Kulisevsky,T. van Laar,Alan Lees,Werner Poewe,A Robillard,MM Rosa,Erik Ch. Wolters,P Quarg,Sibel Tekin,Roger Lane +16 more
TL;DR: In this paper, the effects of the dual cholinesterase inhibitor rivastigmine in patients with mild-to-moderate dementia associated with Parkinson's disease were investigated.
Journal ArticleDOI
Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress
TL;DR: In this paper, the authors explored the profile of neuropsychiatric symptoms in patients with dementia associated with Parkinson's disease (PDD) using the 10-item Neuropsychiatric Inventory (NPI).
Journal Article
Neuropsychiatric symptoms in patients with Parkinson's disease and dementia : frequency, profile and associated care giver stress. Commentary
Iracema Leroi,Alistair Burns,Dag Aarsland,Kolbjørn Brønnick,Uwe Ehrt,P.P. De Deyn,Sibel Tekin,Murat Emre,J. L. Cummings +8 more
TL;DR: Neuropsychiatric symptoms are common in patients with PDD and may be associated with distinct neurobiological changes, which should be explored in future studies.
Journal ArticleDOI
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Howard Feldman,Steven H. Ferris,Bengt Winblad,Nikolaos Sfikas,Linda Mancione,Yunsheng He,Sibel Tekin,Alistair Burns,Jeffrey L. Cummings,Teodoro Del Ser,Domenico Inzitari,Jean Marc Orgogozo,Heinrich Sauer,Philip Scheltens,Elio Scarpini,Nathan Herrmann,Martin R. Farlow,Steven G. Potkin,H. Cecil Charles,Nick C. Fox,Roger Lane +20 more
TL;DR: The overall rate of progression from MCI to AD in this randomised clinical trial was much lower than predicted and the rivastigmine treatment was not associated with any significant safety concerns.
Journal ArticleDOI
Impact of APOE in mild cognitive impairment
TL;DR: MCI subjects carrying the APOE ε4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients, and the genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.